Summary
Danaher Corporation (DHR) reported its first quarter 2025 results, indicating a slight overall revenue decrease of 1.0% year-over-year, with core sales remaining flat. This performance was influenced by varied segment contributions, with the Biotechnology segment showing robust growth while Life Sciences and Diagnostics experienced declines. Net earnings also saw a reduction compared to the prior year, attributed to increased operating expenses, investment losses, and net interest expense. The company is navigating a challenging macroeconomic environment, including the impact of new tariffs, which are expected to add several hundred million dollars in costs, though Danaher aims to offset these through operational adjustments. Despite the top-line softness, Danaher continues to invest in growth and manage its capital effectively. The company repurchased approximately $1.1 billion of its common stock in the quarter and increased its quarterly dividend. The Biotechnology segment demonstrated strong operating profit margin expansion, driven by higher core sales and improved cost structures. However, the Life Sciences and Diagnostics segments faced margin pressures due to lower core sales and specific business mix impacts. Investors should monitor the company's ability to mitigate tariff impacts and drive growth across all segments, particularly in China where certain market dynamics are challenging.
Financial Highlights
50 data points| Revenue | $5.74B |
| Cost of Revenue | $2.23B |
| Gross Profit | $3.51B |
| R&D Expenses | $379.00M |
| SG&A Expenses | $1.86B |
| Operating Income | $1.27B |
| Net Income | $954.00M |
| EPS (Basic) | $1.33 |
| EPS (Diluted) | $1.32 |
| Shares Outstanding (Basic) | 716.30M |
| Shares Outstanding (Diluted) | 720.80M |
Key Highlights
- 1Total revenue declined 1.0% to $5,741 million in Q1 2025 compared to Q1 2024, with core sales remaining flat.
- 2Net earnings decreased to $954 million ($1.32 per diluted share) from $1.1 billion ($1.45 per diluted share) in the prior year's comparable quarter.
- 3The Biotechnology segment was a strong performer, with sales increasing 6.0% and operating profit margins expanding significantly to 27.4% from 21.3%.
- 4Life Sciences and Diagnostics segments experienced sales declines of 3.5% and 3.0% respectively, with corresponding decreases in operating profit margins.
- 5The company anticipates several hundred million dollars in incremental tariff costs in 2025 due to new tariffs, but plans to largely offset these through operational changes.
- 6Danaher repurchased approximately $1.1 billion of its common stock and paid $194 million in dividends in Q1 2025.
- 7Foreign currency exchange rates negatively impacted reported sales by approximately 1.5% in the quarter.